EMA Raises Industry Fees For EU Pharmacovigilance Services
Executive Summary
Companies using the European Medicines Agency’s drug safety services will be paying more from 3 October.
You may also be interested in...
New EU Fee System To Give Pharma Firms More Predictability
The publication of a draft EU Regulation governing the fees paid by the pharmaceutical industry to the European Medicines Agency is the latest step in a long process aimed at ensuring that the payment system better reflects the actual costs of the regulatory work carried out or coordinated by the EU regulator.
EMA Hikes Pharma Industry Fees
This year’s new fee structure at the EMA takes account of the inflation rates in 2020 and 2021 and includes changes relating to inspections and companion diagnostics.
Rare Disease Body Wants EU Legislative Overhaul To Address Orphan Definitions & Incentives
Eurordis has welcomed some parts of the leaked proposals for overhauling the EU medicines legislation, but it has a number of concerns, including the future role of patient representatives if the European Medicines Agency’s committee structure is slimmed down as planned.